JP2016522188A5 - - Google Patents

Download PDF

Info

Publication number
JP2016522188A5
JP2016522188A5 JP2016512076A JP2016512076A JP2016522188A5 JP 2016522188 A5 JP2016522188 A5 JP 2016522188A5 JP 2016512076 A JP2016512076 A JP 2016512076A JP 2016512076 A JP2016512076 A JP 2016512076A JP 2016522188 A5 JP2016522188 A5 JP 2016522188A5
Authority
JP
Japan
Prior art keywords
entinostat
administration
administered
conditions
combination according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016512076A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016522188A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2014/036651 external-priority patent/WO2014179738A1/en
Publication of JP2016522188A publication Critical patent/JP2016522188A/ja
Publication of JP2016522188A5 publication Critical patent/JP2016522188A5/ja
Pending legal-status Critical Current

Links

JP2016512076A 2013-05-03 2014-05-02 癌の処置方法 Pending JP2016522188A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361819505P 2013-05-03 2013-05-03
US61/819,505 2013-05-03
PCT/US2014/036651 WO2014179738A1 (en) 2013-05-03 2014-05-02 Methods for the treatment of cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019026073A Division JP6860949B2 (ja) 2013-05-03 2019-02-15 癌の処置方法

Publications (2)

Publication Number Publication Date
JP2016522188A JP2016522188A (ja) 2016-07-28
JP2016522188A5 true JP2016522188A5 (enExample) 2017-06-15

Family

ID=51843995

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2016512076A Pending JP2016522188A (ja) 2013-05-03 2014-05-02 癌の処置方法
JP2019026073A Active JP6860949B2 (ja) 2013-05-03 2019-02-15 癌の処置方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2019026073A Active JP6860949B2 (ja) 2013-05-03 2019-02-15 癌の処置方法

Country Status (6)

Country Link
EP (1) EP2991650A4 (enExample)
JP (2) JP2016522188A (enExample)
KR (1) KR102337598B1 (enExample)
CN (1) CN105492007A (enExample)
HK (1) HK1223547A1 (enExample)
WO (1) WO2014179738A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3313433A4 (en) * 2015-06-29 2019-01-02 Syndax Pharmaceuticals Inc. Combination of hdac inhibitor and anti-pd-l1 antibody for treatment of cancer
EP3487492A4 (en) * 2016-07-20 2020-03-11 Eisai R&D Management Co., Ltd. USE OF ERIBULIN AND HISTONE DEACETYLASE INHIBITORS FOR THE TREATMENT OF CANCER
EP3624848A1 (en) * 2017-05-19 2020-03-25 Syndax Pharmaceuticals, Inc. Combination therapies
AU2019280822A1 (en) 2018-06-06 2021-01-07 Arena Pharmaceuticals, Inc. Methods of treating conditions related to the S1P1 receptor
RU2680603C1 (ru) * 2018-11-08 2019-02-25 Ильясов Шамиль Сионович Применение 3-о-сульфамата-16,16-диметил-d-гомоэквиленина для лечения онкологических заболеваний

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20080003334A (ko) * 2005-03-11 2008-01-07 더 리젠트스 오브 더 유니버시티 오브 콜로라도 암 세포를 표피 성장 인자 억제제에 대해 감작화시키는히스톤 데아세틸라제 억제제
KR20090037930A (ko) * 2006-07-11 2009-04-16 뮤추얼 파마슈티컬 컴퍼니 아이엔씨. 조절 방출 제형
WO2009067500A1 (en) * 2007-11-19 2009-05-28 Syndax Pharmaceuticals, Inc. Administration of an inhibitor of hdac
CA2719115A1 (en) * 2008-03-07 2009-09-11 Pfizer Inc. Methods, dosage forms, and kits for administering ziprasidone without food
US20110182888A1 (en) * 2008-04-08 2011-07-28 Peter Ordentlich Administration of an Inhibitor of HDAC, an Inhibitor of HER-2, and a Selective Estrogen Receptor Modulator
UA124240U (uk) * 2011-09-02 2018-03-26 Общєство С Огранічєной Отвєтствєностью "Новамєдіка" Спосіб вибору пацієнта для подальшої терапії er-позитивного раку молочної залози

Similar Documents

Publication Publication Date Title
NZ750754A (en) Methods of treating eosinophilic esophagitis
JP2019112416A5 (enExample)
JP2012193216A5 (enExample)
WO2014205229A8 (en) Use of high dose pridopidine for treating huntington's disease
ZA202301198B (en) Method of treating diseases
JP2016520089A5 (enExample)
EP4696301A3 (en) A 19-nor c3,3-disubstituted c21-n-pyrazolyl steroid and methods of use thereof
AR091351A1 (es) Formulaciones de bromocriptina, metodo para mejorar el control glucemico y metodo para la fabricacion
JP2016512817A5 (enExample)
JP2015532293A5 (ja) 糖尿病患者における心不全の治療用組成物
JP2015522603A5 (enExample)
RU2018146504A (ru) Лечение внутрипеченочных холестатических заболеваний
WO2015061790A3 (en) Genetically-associated chronic obstructive pulmonary disease treatment
JP2017514858A5 (enExample)
JP2016501234A5 (enExample)
JP2017061488A5 (enExample)
WO2016122289A3 (ko) 베르베논 유도체를 포함하는 재관류 시술의 부작용을 감소 또는 예방하기 위한 조성물
JP2015512948A5 (enExample)
JP2015535256A5 (enExample)
JP2019513151A5 (enExample)
JP2016514142A5 (enExample)
Elleuch et al. Complete radiological response after sorafenib treatment for advanced hepato-cellular carcinoma
MD4317B1 (en) Use of 3-(2,2,2-trimethylhydrazinium)propionate dihydrate for treating patients with advanced liver cirrhosis associated with heart failure
RU2011108787A (ru) Способ лечения больных красным плоским лишаем слизистой полости рта
MD596Y (en) Method for treating the chronic viral hepatitis C